Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 13/20 | 0.52 |
| ▸ | JUN | P05412 | 6/20 | 0.52 |
| ▸ | NFKB2 | Q00653 | 6/20 | 0.52 |
| ▸ | RELA | Q04206 | 6/20 | 0.52 |
| ▸ | ATF1 | P18846 | 8/20 | 0.40 |
| ▸ | XPO1 | O14980 | 4/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | ULK1 | O75385 | 1/20 | 0.38 |
| ▸ | PLK1 | P53350 | 1/20 | 0.37 |
| ▸ | NNMT | P40261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30498347 | 0.88 | NFKB1 (0.49) | NFKB1JUNNFKB2RELAATF1 | |
| SCHEMBL5570021 | 0.83 | NFKB1 (0.54) | NFKB1JUNNFKB2RELAATF1 | |
| SCHEMBL6643357 | 0.81 | NFKB1 (0.49) | NFKB1JUNNFKB2RELAATF1 | |
| SCHEMBL4768472 | 0.81 | NFKB1 (0.52) | NFKB1JUNNFKB2RELAATF1 | |
| SCHEMBL1320432 | 0.79 | NFKB1 (0.49) | NFKB1JUNNFKB2RELAATF1 | |
| SCHEMBL30110408 | 0.78 | NFKB1 (0.46) | NFKB1JUNNFKB2RELAATF1 | |
| SCHEMBL1602748 | 0.78 | NFKB1 (0.46) | NFKB1JUNNFKB2RELAATF1 | |
| SCHEMBL17681993 | 0.77 | NFKB1 (0.49) | NFKB1JUNNFKB2RELAATF1 | |
| SCHEMBL429969 | 0.76 | NFKB1 (0.46) | NFKB1JUNNFKB2RELAATF1 | |
| SCHEMBL31469871 | 0.76 | NFKB1 (0.46) | NFKB1JUNNFKB2RELAATF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250257051-A1 | SUBSTITUTED PYRIMIDINE COMPOUNDS AS TYK2 INHIBITORS | 1910 GENETICS INC (US) | 2025-08-14 | — | — | US | disclosed |
| US-20250115597-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO LTD (CN) | 2025-04-10 | — | — | US | disclosed |
| US-12129250-B2 | TYK2 inhibitors and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-10-29 | — | — | US | disclosed |
| EP-4448514-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | Lynk Pharmaceuticals Co. Ltd. (CN) | 2024-10-23 | — | — | EP | disclosed |
| US-20240124448-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-04-18 | — | — | US | disclosed |
| WO-2024026430-A1 | SUBSTITUTED PYRIMIDINE COMPOUNDS AS TYK2 INHIBITORS | 1910 GENETICS INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| US-11780801-B2 | Methods of synthesis of (1R,2R,5R)-5-amino-2-methyl-cyclohexanol hydrochloride and intermediates useful therein | CELGENE CORPORATION (US) | 2023-10-10 | — | — | US | disclosed |
| WO-2023108536-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023109954-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023109120-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2023-06-22 | — | — | WO | disclosed |
| US-9145387-B2 | ERK inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-9145387-B2 | ERK inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| WO-2014124230-A2 | ERK INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-08-14 | — | — | WO | disclosed |
| WO-2014124230-A2 | ERK INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-08-14 | — | — | WO | disclosed |
| US-20140228322-A1 | ERK INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-08-14 | — | — | US | disclosed |
| US-20140228322-A1 | ERK INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-08-14 | — | — | US | disclosed |
| US-20140228322-A1 | ERK INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-08-14 | — | — | US | disclosed |
| WO-2012059507-A1 | PYRROLIDINE DERIVATIVES USED AS CATHEPSIN INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-05-10 | — | — | WO | disclosed |
| US-20090209743-A1 | COLOURED ORGANOPOLYSILOXANES | DYSTAR COLOURS DEUTSCHLAND GMBH (DE) | 2009-08-20 | — | — | US | disclosed |
| US-20090209743-A1 | COLOURED ORGANOPOLYSILOXANES | DYSTAR COLOURS DEUTSCHLAND GMBH (DE) | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209743-A1 | COLOURED ORGANOPOLYSILOXANES | MSR1, ARSA, HBS1L | NFKB1 2972/4885JUN 4868/4885NFKB2 2146/4885 |
| US-11780801-B2 | Methods of synthesis of (1R,2R,5R)-5-amino-2-methyl-cyclohexanol hydrochloride and intermediates useful therein | MAPKAPK2, MAP3K8, MAPK1 | NFKB1 933/4885JUN 47/4885NFKB2 1418/4885 |
| US-20240124448-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | TYK2, JAK2, JAK1 | NFKB1 1884/4885JUN 2243/4885NFKB2 1677/4885 |
| US-20250115597-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | TYK2, JAK2, JAK1 | NFKB1 1884/4885JUN 2243/4885NFKB2 1677/4885 |
| US-12129250-B2 | TYK2 inhibitors and compositions and methods thereof | TYK2, JAK2, JAK1 | NFKB1 1884/4885JUN 2243/4885NFKB2 1677/4885 |
| US-20250257051-A1 | SUBSTITUTED PYRIMIDINE COMPOUNDS AS TYK2 INHIBITORS | TYK2, PDXK, JAK1 | NFKB1 1372/4885JUN 1566/4885NFKB2 1533/4885 |
| US-20140228322-A1 | ERK INHIBITORS AND USES THEREOF | MAP3K20, MAP3K1, MAPK3 | NFKB1 1659/4885JUN 518/4885NFKB2 1841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.